The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict DepoMed's revenues will grow 67.9% and EPS will remain in the red.
The average estimate for revenue is $28.3 million. On the bottom line, the average EPS estimate is -$0.06.
Last quarter, DepoMed chalked up revenue of $26.6 million. GAAP reported sales were much higher than the prior-year quarter's $12.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.07. GAAP EPS were -$0.07 for Q4 against -$0.25 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 88.7%, 620 basis points worse than the prior-year quarter. Operating margin was -17.3%, much better than the prior-year quarter. Net margin was -13.9%, much better than the prior-year quarter.
The full year's average estimate for revenue is $128.9 million. The average EPS estimate is -$0.02.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 226 members out of 243 rating the stock outperform, and 17 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 45 give DepoMed a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DepoMed is buy, with an average price target of $9.33.
- Add DepoMed to My Watchlist.